Sarepta Therapeutics Shares Soar as FDA Lifts Partial Hold on Elevidys Shipments
WASHINGTON (AP) — Shares of biotech firm Sarepta Therapeutics experienced a significant surge in after-hours trading Monday, jumping more than 16% to $13.86. The dramatic increase came after the company announced the U.S. Food and Drug Administration (FDA) had recommended lifting a brief clinical hold on shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, for a specific patient group.
Elevidys: A Breakthrough in Duchenne Treatment
Elevidys holds a pivotal position as the first gene therapy to receive U.S. approval for Duchenne muscular dystrophy, a rare and devastating genetic disorder. Primarily affecting boys, Duchenne leads to progressive muscle degeneration and weakness, often resulting in severe disability and premature death, typically by early adulthood. The therapy received an accelerated approval in 2023 for a narrow range of young, ambulatory patients and its use was expanded last year to include older patients, even those who have lost the ability to walk.
Safety Concerns and Regulatory Response
The FDA’s temporary pause in shipments was prompted by serious safety concerns, specifically the deaths of two older teenage patients who were receiving the therapy. These fatalities were linked to acute liver injury, a known potential side effect associated with this type of gene therapy. Adding to the regulatory pressure, a third patient death involving an 8-year-old boy, who was undergoing a different Sarepta therapy, had been recently reported. However, a crucial determination by the FDA stated that this particular death was found to be unrelated to Elevidys.
Partial Lift of Clinical Hold: Focus on Ambulatory Patients
The FDA’s latest decision clarifies that the hold is lifted only for young patients with Duchenne who are still able to walk. This targeted approval allows Sarepta to resume shipments to this sub-group, offering renewed hope for families and clinicians. However, the agency’s statement explicitly noted that the voluntary hold for non-ambulatory patients remains in place. This indicates continued caution and a demand for more comprehensive safety data from Sarepta before broader usage can be considered.
Market Optimism Amidst Ongoing Challenges
The market’s immediate response underscores the high stakes involved in the development of life-saving therapies. Jefferies analyst Andrew Tsai noted that the FDA’s decision “significantly improves Elevidys’ sales outlook in the near-term,” providing “meaningful stock upside potential” and a sense of relief for investors. Despite this positive development, Sarepta still faces the formidable task of addressing the FDA’s call for new study data to ensure the therapy’s safety and efficacy for all Duchenne patients, particularly those in more advanced stages of the disease. The path forward for Elevidys, especially for its use in older, non-ambulatory patients, remains subject to rigorous ongoing regulatory review.
